admin
HAVANA. — Cuban-made monoclonal antibody Nimotuzumab, widely considered as a “promising” cancer treatment, has been registered in 28 countries, the official daily Granma reported on Tuesday.
The antibody has proven effective in treating malignant tumours in the head and neck, and is also being applied in cases of colorectal oncogenic disease, liver and lung cancer, brain metastases and other diseases, the daily reported, citing specialists at Cuba’s Immunology Molecular Centre.
Key figures in the field of medical biotechnology research around the globe have validated the treatment, the paper said.
To showcase the results of Nimotuzumab efficacy trials and the treatment’s new indications, the seventh Scientific Global Meeting on Nimotuzumab opened on Tuesday at the Havana Convention Centre.
The forum brings together more than 200 experts from 20 countries and regions interested in sharing experiences. — Xinhua.
Peter Tanyanyiwa
Online Reporter